Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Gpc Biotech
Evaluate
December 21, 2010
Who were the cash call kings of 2010?
January 26, 2010
Poniard's happy talk masks dire future for picoplatin
July 03, 2009
CombinatoRx finds that reversing is the way forward
February 18, 2009
GPC hoping to reverse out of trouble
July 22, 2008
Abiraterone data adding weight to Cougar and BTG
May 09, 2008
Wilex and GPC contemplating engagement?
December 18, 2007
The winners and losers of 2007
November 28, 2007
Prostate cancer results power Cougar Biotech's shares
November 27, 2007
Neurocrine unlikely to wake up market with approval
November 22, 2007
VANTAGE EXCLUSIVE - Algeta in deal talks
November 06, 2007
Novacea's Asentar is second set back in two weeks for advanced prostate cancer
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics